Biotech IPOs Return with Kailera and Alamar
Biotech IPOs have made a strong comeback with Kailera Therapeutics and Alamar Biosciences raising significant funds. Kailera raised $625 million, while Alamar raised $191.3 million, both exceeding their initial targets and seeing strong first-day gains. This marks a shift in investor sentiment toward life sciences companies.
Topics: Alamar Biosciences biotech IPO Kailera Therapeutics market trends Nasdaq